Lisando starts up in BioRegio Regensburg
Lisando GmbH was founded by Dr. Stefan Miller, who has been working for many years with bacterial organisms and their natural opponents, bacteriophages. Dr. Miller was one of the founders and on the scientific board of directors for many years of the former company Profos AG. In his new company he is concentrating on active substances effective against gram-negative bacteria such as pseudomonas and salmonella, which can cause life threatening infections including pulmonary infections, wound infection and diarrhoeal illness. Lisando is developing novel technologies to combat these resistant bacteria, which are often difficult to control with regular means. The technique is based on an effective mechanism seen in nature: bacteriophages, the natural enemies of bacteria, form proteins with which they destroy gram-negative bacteria precisely and effectively. On the basis of these bacteriophage proteins, Lisando is designing and optimising effective antibacterial active substances, which can be used everywhere where gram-negative bacteria represent a source of contamination or risk of infection. The spectrum ranges from applications in the field of food production for human and animal consumption to disinfection in the clinical field or in mass production. Bacterial infection does not constitute solely a risk to individual health, but also causes in addition to treatment costs considerable national economic follow-on costs. In the USA the total economic load has been estimated at 4.5 billion US$ for hospital-acquired nosocomial infections.
For further information see: